Literature DB >> 21321061

Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia.

Sophie J Bradley1, Christopher J Langmead, Jeannette M Watson, R A John Challiss.   

Abstract

Positive and negative allosteric modulators (PAMs and NAMs, respectively) of the type 5 metabotropic glutamate (mGlu5) receptor have demonstrable therapeutic potential in an array of neurological and psychiatric disorders. Here, we have used rat cortical astrocytes to investigate how PAMs and NAMs mediate their activity and reveal marked differences between PAMs with respect to their modulation of orthosteric agonist affinity and efficacy. Affinity cooperativity factors (α) were assessed using [(3)H]2-methyl-6-(phenylethynyl)-pyridine (MPEP)-PAM competition binding in the absence and presence of orthosteric agonist, whereas efficacy cooperativity factors (β) were calculated from net affinity/efficacy cooperativity parameters (αβ) obtained from analyses of the abilities of PAMs to potentiate [(3)H]inositol phosphate accumulation in astrocytes stimulated with a submaximal (EC(20)) concentration of orthosteric agonist. We report that whereas 3,3'-difluorobenzaldazine (DFB) and 3-cyano-N-(1,3-diphenyl-1H-prazol-5-yl)benzamide (CDPPB) primarily exert their allosteric modulatory effects through modifying the apparent orthosteric agonist affinity at the astrocyte mGlu5 receptor, the effects of S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidinl-1-yl}-methanone (ADX47273) are mediated primarily via efficacy-driven modulation. In [(3)H]MPEP-NAM competition binding assays, both MPEP and 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine (M-5MPEP) defined similar specific binding components, with affinities that were unaltered in the presence of orthosteric agonist, indicating wholly negative efficacy-driven modulations. It is noteworthy that whereas M-5MPEP only partially inhibited orthosteric agonist-stimulated [(3)H]inositol phosphate accumulation in astrocytes, it could completely suppress Ca(2+) oscillations stimulated by quisqualate or (S)-3,5-dihydroxyphenylglycine. In contrast, MPEP was fully inhibitory with respect to both functional responses. The finding that M-5MPEP has different functional effects depending on the endpoint measured is discussed as a possible example of permissive allosteric antagonism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321061      PMCID: PMC3082933          DOI: 10.1124/mol.110.068882

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

Review 1.  Recent progress in the development of allosteric modulators of mGluR5.

Authors:  Alice L Rodriguez; Richard Williams
Journal:  Curr Opin Drug Discov Devel       Date:  2007-11

Review 2.  Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs.

Authors:  Joanna M Wierońska; Andrzej Pilc
Journal:  Neurochem Int       Date:  2009-03-09       Impact factor: 3.921

3.  [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization.

Authors:  Jeffery J Anderson; Sara P Rao; Blake Rowe; Darlene R Giracello; Greg Holtz; Deborah F Chapman; Lida Tehrani; Margaret J Bradbury; Nicholas D P Cosford; Mark A Varney
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

4.  Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses.

Authors:  Yelin Chen; Yi Nong; Cyril Goudet; Kamondanai Hemstapat; Tomas de Paulis; Jean-Philippe Pin; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2007-02-15       Impact factor: 4.436

Review 5.  Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome.

Authors:  Gül Dölen; Mark F Bear
Journal:  J Physiol       Date:  2008-01-17       Impact factor: 5.182

Review 6.  Distinct roles of group I mGlu receptors in striatal function.

Authors:  P Bonsi; P Platania; G Martella; G Madeo; D Vita; A Tassone; G Bernardi; A Pisani
Journal:  Neuropharmacology       Date:  2008-07-07       Impact factor: 5.250

Review 7.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Arthur Christopoulos; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

Review 8.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.

Authors:  Katie Leach; Patrick M Sexton; Arthur Christopoulos
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

9.  ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.

Authors:  Feng Liu; Steve Grauer; Cody Kelley; Rachel Navarra; Radka Graf; Guoming Zhang; Peter J Atkinson; Michael Popiolek; Caitlin Wantuch; Xavier Khawaja; Deborah Smith; Michael Olsen; Evguenia Kouranova; Margaret Lai; Farhana Pruthi; Claudine Pulicicchio; Mark Day; Adam Gilbert; Mark H Pausch; Nicholas J Brandon; Chad E Beyer; Tom A Comery; Sheree Logue; Sharon Rosenzweig-Lipson; Karen L Marquis
Journal:  J Pharmacol Exp Ther       Date:  2008-08-27       Impact factor: 4.030

10.  N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors.

Authors:  Yelin Chen; Cyril Goudet; Jean-Philippe Pin; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2007-12-04       Impact factor: 4.436

View more
  13 in total

Review 1.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

Review 2.  Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

3.  Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation.

Authors:  Karen J Gregory; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2015-03-25       Impact factor: 4.436

Review 4.  Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models.

Authors:  David Roche; Debora Gil; Jesús Giraldo
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

5.  Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators.

Authors:  Daniel E O'Brien; Douglas M Shaw; Hyekyung P Cho; Alan J Cross; Steven S Wesolowski; Andrew S Felts; Jonas Bergare; Charles S Elmore; Craig W Lindsley; Colleen M Niswender; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2018-03-15       Impact factor: 4.436

6.  A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling.

Authors:  M J Noetzel; K J Gregory; P N Vinson; J T Manka; S R Stauffer; C W Lindsley; C M Niswender; Z Xiang; P J Conn
Journal:  Mol Pharmacol       Date:  2013-01-24       Impact factor: 4.436

7.  Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships.

Authors:  Karen J Gregory; Meredith J Noetzel; Jerri M Rook; Paige N Vinson; Shaun R Stauffer; Alice L Rodriguez; Kyle A Emmitte; Ya Zhou; Aspen C Chun; Andrew S Felts; Brian A Chauder; Craig W Lindsley; Colleen M Niswender; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2012-08-03       Impact factor: 4.436

8.  VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.

Authors:  Hilary Highfield Nickols; Joannes P Yuh; Karen J Gregory; Ryan D Morrison; Brittney S Bates; Shaun R Stauffer; Kyle A Emmitte; Michael Bubser; Weimin Peng; Michael T Nedelcovych; Analisa Thompson; Xiaohui Lv; Zixiu Xiang; J Scott Daniels; Colleen M Niswender; Craig W Lindsley; Carrie K Jones; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2015-10-26       Impact factor: 4.030

9.  Allosteric transition: a comparison of two models.

Authors:  Niels Bindslev
Journal:  BMC Pharmacol Toxicol       Date:  2013-01-08       Impact factor: 2.483

Review 10.  Plasticity of Neuron-Glial Transmission: Equipping Glia for Long-Term Integration of Network Activity.

Authors:  Wayne Croft; Katharine L Dobson; Tomas C Bellamy
Journal:  Neural Plast       Date:  2015-08-03       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.